Stable Cell Line Producing CHIKV Virus-Like Particles
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccine platforms for Chikungunya Virus (CHIKV) are expensive and inefficient, particularly for developing countries, as they require repeated transfection of cells to produce Virus Like Particles (VLPs) for vaccine production.
Innovation Solution
A stable cell line is developed using a lentiviral system that constitutively expresses CHIKV structural proteins, optimized to produce VLPs in a consensus sequence relevant to current outbreaks, with improved production and purification methods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If repeated transfection of cells is used to produce VLPs, then VLP production is achieved, but production cost increases and efficiency decreases
Solution Approach 1:
The patent applies preliminary action by pre-integrating the CHIKV structural protein genes into the cell genome through stable transfection, creating a cell line that constitutively expresses VLPs. This eliminates the need for repeated transfections, thereby reducing production costs and improving efficiency while maintaining continuous VLP production capability
Solution Approach 2:
The stable cell line automatically produces VLPs through constitutive expression of the integrated viral protein genes. The system serves itself by continuously generating VLPs without requiring external intervention or repeated transfection procedures, thereby reducing both cost and operational complexity
2Ease of manufacture
If stable cell line is used to produce VLPs, then production cost decreases and efficiency improves, but vaccine platform complexity increases
Solution Approach 1:
The complexity of creating a stable cell line is performed as a preliminary action during the vaccine development phase. Once the stable cell line is established with integrated viral genes, it provides long-term, cost-effective VLP production without requiring repeated complex transfection procedures, thus amortizing the initial complexity over extended production periods
Data Source
AI summary
The present invention includes nucleic acids, proteins, Chikungunya virus (CHIKV) Virus Like Particles (VLP), and methods of making a Chikungunya virus (CHIKV) Virus Like Particles (VLP) comprising: inserting one or more nucleic acids into a lentiviral backbone, wherein the nucleic acid encodes one or more Chikungunya virus (CHIKV) proteins; transfecting the one or more nucleic acids into the lentiviral backbone into a cell line; culturing the transfected cell line under conditions in which the Chikungunya virus (CHIKV) Virus Like Particles (VLP) are released from the cell line; and isolating the Chikungunya virus (CHIKV) Virus Like Particles (VLP) from a culture supernatant.